€36.66
Your prediction
Eckert & Ziegler Strahlen- und Medizintechnik AG Stock
Pros and Cons of Eckert & Ziegler Strahlen- und Medizintechnik AG in the next few years
Pros
Cons
Performance of Eckert & Ziegler Strahlen- und Medizintechnik AG vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Eckert & Ziegler Strahlen- und Medizintechnik AG | 1.160% | 9.091% | -4.481% | -22.065% | -12.337% | -52.441% | 92.000% |
Geratherm Medical AG | -2.930% | -0.485% | -9.692% | -44.966% | -24.771% | -65.401% | -57.292% |
Paul Hartmann AG | -0.470% | 0.476% | 1.442% | -6.637% | 2.927% | -45.052% | - |
Stratec SE | 3.630% | 0.251% | -4.762% | -35.380% | -12.854% | -64.476% | -36.204% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, the financials of Eckert & Ziegler seem to reflect a growing and healthy company within the Healthcare Equipment & Supplies industry. Over the past few years, there has been a consistent increase in total assets, revenue, and net income, among other financial indicators. This initial impression suggests that the company may be a promising investment for those interested in the healthcare equipment sector.
Pros:
Revenue Growth: Eckert & Ziegler has demonstrated consistent growth in revenue over the past three years. From 2019 to 2021, the total revenue has increased from €178.49 million to €180.44 million, indicating a positive trend in the company's operations and business prospects.
Comments
Eckert & Ziegler ist ein Strahlen- und Medizintechnikkonzern mit vielversprechenden Projekten in der Pipeline, die trotz eines Gewinnrückgangs im laufenden Jahr Analysten zum Kauf der Aktie raten lassen. Das Unternehmen ist aufgrund seines One-Stop-Shop-Produktangebots und seiner weltweiten Aufstellung bestens positioniert, um sein margenstarkes Radiopharma-Geschäft in den kommenden Jahren deutlich zu steigern.